Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Dominari Holdings Inc

Dominari Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.95
  • Today's Change0.09 / 4.84%
  • Shares traded23.33k
  • 1 Year change-20.41%
  • Beta0.9415
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dominari Holdings Inc. is a holding company. The Company, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading and asset management. It operates through its wholly owned subsidiaries, including Dominari Financial Inc. (Dominari Financial) and Dominari Securities LLC (Dominari Securities). Dominari Securities offers and plans to offer a range of broker-dealer and registered investment adviser services. Its services include wealth management, investment banking, sales and trading, asset management and insurance products. Dominari Securities provides a comprehensive array of financial services to high-net-worth individuals and families, corporate executives, and public and private businesses. Dominari Securities also provides full-service brokerage, wealth planning and margin lending services. Dominari Securities’ investment banking division provides strategic advisory services and capital markets products to middle market businesses.

  • Revenue in USD (TTM)9.51m
  • Net income in USD-22.02m
  • Incorporated1992
  • Employees26.00
  • Location
    Dominari Holdings Inc725 FIFTH AVENUE, 22ND FLOORNEW YORK 10022United StatesUSA
  • Phone+1 (212) 393-4540
  • Fax+1 (302) 674-5266
  • Websitehttps://aikidopharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Avalo Therapeutics Inc807.00k-36.22m10.05m19.00------12.46-63.82-63.820.3347-2.080.0122--20.9642,473.68-54.66-99.64-529.15-154.4264.1984.69-4,488.60-613.58---------89.34-22.8324.28---22.48--
Nymox Pharmaceutical Corp0.00-8.84m10.29m3.00---------0.0966-0.09660.00-0.03390.00-------785.44-306.39---749.37-------43,683.47---157.57---------34.49---39.16--
Forte Biosciences Inc0.00-35.76m10.34m11.00--0.6085-----22.03-22.030.0011.640.00----0.00-124.89-72.06-170.91-82.27-------491,850.00----0.00-------126.79---46.29--
Enzon Pharmaceuticals Inc26.00k314.00k10.45m0.0033.293.44--401.900.00420.00420.00040.62770.0006------3.39-0.86543.42-0.8851----6,111.54-159.43----0.00---100.00--106.71-55.86----
Kineta Inc0.00-20.88m10.54m11.00---------1.79-1.790.00-0.66380.00----0.00-220.35-66.16---86.61-------854.74--------178.6513.8977.76------
Yubo International Biotech Ltd454.29k-1.42m10.54m18.00------23.21-0.0118-0.01180.0038-0.02110.24620.59863.4925,238.33-82.33------80.30---334.36--0.1707-4,795.69----479.86--0.8224------
GlycoMimetics Inc10.00k-39.11m10.63m35.00--0.5297--1,062.70-0.6071-0.60710.00020.31110.0002--0.0685285.71-90.71-43.60-103.87-47.82-----391,132.40-2,243.52----0.00---86.67--20.97---29.82--
Kiora Pharmaceuticals Inc16.02m2.67m10.87m12.00--0.32854.030.6787-7.76-7.766.6111.140.5279--7.161,335,000.0010.54-70.5211.20-81.86----19.98-2,040.61----0.00------3.97------
Dominari Holdings Inc9.51m-22.02m11.67m26.00--0.2742--1.23-3.85-3.851.676.780.1629--2.60365,730.80-37.71-26.82-39.96-27.45-----231.55-3,353.52---5.050.00----135.7512.72--63.99--
Tenax Therapeutics Inc0.00-12.57m12.17m5.00--0.7876-----22.35-22.350.004.530.00----0.00-101.95-199.16-113.79-285.64-----------95.940.0305------30.21------
Vaccinex Inc356.00k-17.76m12.35m37.00------34.69-24.59-24.590.3183-1.810.1306--0.67429,621.62-651.39-262.29---------4,987.92-4,257.17---52.60----107.27-4.67-2.20---22.20--
Aspira Women's Health Inc8.92m-15.95m12.95m64.00------1.45-1.45-1.450.801-0.28921.5315.115.79139,421.90-273.16-110.58-3,758.30-151.8857.8445.23-178.80-334.080.5542-17,354.00----11.8524.5644.15---26.65--
BioRestorative Therapies Inc174.10k-8.00m13.29m11.00--1.23--76.31-1.22-1.220.0291.560.0118--6.6515,827.27-54.42-192.11-68.75-329.3247.45---4,597.79-19,116.15----0.00--21.705.6143.67--67.77--
Data as of Sep 23 2024. Currency figures normalised to Dominari Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

7.97%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2024193.39k3.26%
BlackRock Fund Advisorsas of 31 Mar 202472.52k1.22%
Geode Capital Management LLCas of 30 Jun 202446.11k0.78%
Renaissance Technologies LLCas of 30 Jun 202445.93k0.77%
Dimensional Fund Advisors LPas of 30 Jun 202439.83k0.67%
Bridgeway Capital Management LLCas of 31 Mar 202420.50k0.35%
SSgA Funds Management, Inc.as of 31 Mar 202419.99k0.34%
Two Sigma Advisers LPas of 31 Mar 202418.20k0.31%
G1 Execution Services LLCas of 31 Mar 202412.14k0.21%
Tower Research Capital LLCas of 31 Mar 20244.04k0.07%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.